Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma

• DOI: 10.1016/j.ijrobp.2019.06.079
• Publication Date: 2019-06-19T11:18:28Z
• Authors: Dong Qian; Yuwen Wang; Gang Zhao; Fuliang Cao; Puchun Er; Xi Chen; Jingjing Cheng; Wencheng Zhang; Xiaoxia Li; Baozhong Zhang; Yong Guan; Dejun Zhou; Jun Wang; Hongjing Jiang; Zhentao Yu; Zhiyong Yuan; Ping Wang; Qingsong Pang
• Keywords: Tumor-infiltrating lymphocytes; Neoadjuvant Therapy

Clinical tools are unavailable for accurate prediction of pathologic responses to chemoradiation therapy (CRT) among patients with esophageal squamous cell carcinoma (ESCC) before surgery. We evaluated tumor remission and tumor-infiltrating lymphocytes (TILs) during CRT as predictors response prognostic markers locally advanced ESCC treated neoadjuvant (neo-CRT) or definitive CRT.We analyzed (N = 164) who underwent neo-CRT 48) 116). Patients endoscopic ultrasonography biopsies when induction finished. Tumor characteristics were designated minor (-/+) excellent (ER) (+++). TILs determined in 10% increments. remission, TILs, both associated complete (pCR) survival the group then group.ER lymphocyte-predominant (LPE; ≥60% TILs) identified according pCR rate disease-free survival. built a model incorporating ER LPE. The area under receiver operating characteristic curve was 0.877, sensitivity specificity 86.7% 90.9%, respectively. Furthermore, this an calibration. Disease-free LPE tumors significantly longer than that other patients.When we included CRT, our predicted high probability helped stratify subgroups, thereby guiding future decisions ESCC. Validation larger, prospective, multicenter studies is essential.